Extension of Postponement for R&D Expense Receipt from Vanda Pharmaceuticals
Correction of disclosure: Extension of postponement deadline for R&D expense receipt from Vanda Pharmaceuticals to 2026-05-31 (correction date 2026-04-30).
Received R&D expenses from Vanda Pharmaceuticals (fact date 2023-10-16). Amount undisclosed but exceeds 10% of the company's 2022 sales (approx. KRW 2.3 billion), making it material.
The amount is recognized as R&D revenue and kept confidential until the contract term at Vanda's request.
Previous postponement deadline extended from 2026-04-30 to 2026-05-31.
KOSDAQ Filing Information
Filing: [Correction of Description] Major Management Matters Related To Investment Decision (Receipt Of R&D Expenses For Joint Research And Development Of New Drug)